SMARCAL1: Expanding the spectrum of genes associated with alternative lengthening of telomeres

Affiliations

Editorial

Cristiane M Ida et al. Neuro Oncol. 2023.

. 2023 Sep 5;25(9):1576-1577.

doi: 10.1093/neuonc/noad084.

¹ Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

No abstract available

Comment on

Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
Liu H, Xu C, Diplas BH, Brown A, Strickland LM, Yao H, Ling J, McLendon RE, Keir ST, Ashley DM, He Y, Waitkus MS. Liu H, et al. Neuro Oncol. 2023 Sep 5;25(9):1563-1575. doi: 10.1093/neuonc/noad022. Neuro Oncol. 2023. PMID: 36689342 Free PMC article.

1. Hanahan D, Weinberg RA.. The hallmarks of cancer. Cell. 2000;100(1):57–70. - PubMed
1. Shay JW, Bacchetti S.. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33(5):787–791. - PubMed
1. Killela PJ, Reitman ZJ, Jiao Y, et al. . TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 2013;110(15):6021–6026. - PMC - PubMed
1. Gupta S, Vanderbilt CM, Lin YT, et al. . A pan-cancer study of somatic TERT promoter mutations and amplification in 30,773 tumors profiled by clinical genomic sequencing. J Mol Diagn. 2021;23(2):253–263. - PMC - PubMed
1. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR.. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med. 1997;3(11):1271–1274. - PubMed